Emergent BioSolutions/$EBS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Emergent BioSolutions
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
- Ticker
- $EBS
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 900
- Headquarters
- Gaithersburg, United States
- Website
- www.emergentbiosolutions.com
EBS Metrics
BasicAdvanced
$312M
-
-$5.04
2.37
-
Price and volume
Market cap
$312M
Beta
2.37
52-week high
$14.06
52-week low
$4.36
Average daily volume
1.1M
Financial strength
Current ratio
4.575
Quick ratio
2.075
Long term debt to equity
1.621
Total debt to equity
1.621
Interest coverage (TTM)
0.65%
Profitability
EBITDA (TTM)
125.7
Gross margin (TTM)
43.41%
Net profit margin (TTM)
-40.16%
Operating margin (TTM)
5.81%
Effective tax rate (TTM)
-8.63%
Revenue per employee (TTM)
$720,000
Management effectiveness
Return on assets (TTM)
1.51%
Return on equity (TTM)
-58.21%
Valuation
Price to revenue (TTM)
0.483
Price to book
0.99
Price to tangible book (TTM)
5.12
Price to free cash flow (TTM)
2.233
Free cash flow yield (TTM)
44.78%
Free cash flow per share (TTM)
2.714
Growth
Revenue change (TTM)
-17.72%
Earnings per share change (TTM)
-470.57%
3-year revenue growth (CAGR)
-16.20%
10-year revenue growth (CAGR)
2.71%
3-year earnings per share growth (CAGR)
-31.06%
10-year earnings per share growth (CAGR)
16.91%
What the Analysts think about EBS
Analyst ratings (Buy, Hold, Sell) for Emergent BioSolutions stock.
Analyst projections of the future price of Emergent BioSolutions stock.
Bulls say / Bears say
Medical countermeasures are showing strong demand: Q2 MCM revenue reached $168 million, and Emergent has since secured a further $24 million US anthrax-vaccine contract modification. International sales also offer some diversification from US government orders. (Emergent BioSolutions, Emergent BioSolutions)
The balance sheet is improving: Emergent refinanced its term loan to extend maturity to 2031 and reduce interest costs, then repurchased $75 million of unsecured notes for about $68 million. That lowers debt and eases near-term financing pressure. (Emergent BioSolutions, GlobeNewswire)
A restructuring focused on workforce and facilities is expected to deliver about $40 million in annual savings once fully implemented. If achieved, those savings could help offset pressure elsewhere in the business. (Emergent BioSolutions)
NARCAN faces tougher competition and pricing pressure from new entrants, prompting Emergent to cut its 2026 revenue outlook and record a $191.3 million impairment. Q2 commercial revenue fell to $52.4 million from $67.5 million a year earlier. (SEC, Emergent BioSolutions)
The Q2 revenue surge was helped by accelerated medical-countermeasure deliveries, which may make quarterly performance uneven. Government procurement funding and delivery timing remain risks to this contract-led business. (Emergent BioSolutions, SEC)
Refinancing risk remains despite the bond buyback: about $365 million of unsecured notes are still due in August 2028. S&P moved its outlook to negative, citing pressure on cash generation and uncertainty about refinancing. (GlobeNewswire, Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 16 Oct 2026.
EBS Financial Performance
Revenues and expenses
EBS Earnings Performance
Company profitability
Upcoming events
No upcoming events
EBS News
AllArticlesVideos
Funds containing EBS
Fund name | Fund size | $EBS weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.